Changes in estrone and estradiol levels during follicle development: a retrospective large-scale study
Reproductive Biology and Endocrinologyvolume 13, Article number: 54 (2015)
The improved reagent for measuring estradiol (E2), the ST AIA-PACK iE2 reagent, has a higher specificity for the measurement of E2 levels than the original ST AIA-PACK E2 reagent, because of its lower cross-reactivity with estrone (E1). As we had E2 data obtained with either of the reagents, we analyzed changes in E1 and E2 levels during follicle development.
The study included 14371 serum hormone measurements from 4412 patients who underwent oocyte retrieval or frozen/thawed embryo transfer in natural cycle in vitro fertilization in Shinbashi YUME clinic, Tokyo, between June 2011 and May 2014. The age of the patients ranged from 24 to 48 year (mean and standard deviation, 39.8 ± 4.0 year). Patients were categorized into three age groups (<38 year, 38–40 year, and >40 year) and into 10 groups of largest follicle diameter from 11 to 20 mm, with 1-mm intervals. Serum E2 levels were measured in the follicular phase with either the ST AIA-PACK E2 reagent or the ST AIA-PACK iE2 reagent, and the data were compared. Also, for 26 randomly selected samples, E2 was measured using both reagents, together with E1 and E3, and the E1/E2 ratios were compared.
E2 concentrations measured with the ST AIA-PACK iE2 reagent were significantly lower than those measured with the ST AIA-PACK E2 reagent in the largest follicle diameter category of 11–17 mm in the <38 year group, in the largest follicle diameter category of 11–18 mm in the 38–40 year group, and in the largest follicle diameter category of 11–15 mm in the >40 year group. The serum E1/E2 ratio in the 26 samples was 3.4 ± 1.1 and 0.7 ± 0.1 in the early follicular phase and in the ovulatory phase, respectively.
The difference between the E2 concentrations measured with the ST AIA-PACK E2 reagent and the ST AIA-PACK iE2 reagent tended to decrease as the follicle diameter increased, particularly in the older patients, which suggests E1 secretion is more abundant in the early follicular phase and in younger patients than in the ovulatory phase and in older patients.
The serum estradiol (E2) concentration is used to evaluate follicle maturation. This measurement is essential to predict the timing of ovulation when treating infertility patients. As the date of ovulation approaches, the E2 level changes dynamically day-by-day, particularly in natural cycle in vitro fertilization (IVF). In pre-menopausal women, E2 is mainly secreted by granulosa cells in the follicles. As these cells divide and proliferate within a follicle, increasing in number as the follicle grows, the E2 level also increases. Thus, the E2 concentration is a good index of follicular maturation. Menopausal and post-menopausal women, as well as obese women, have elevated serum levels of estrone (E1), and E1 is also secreted by tissues other than the ovary [1–6]. However, the action and role of E1 and its secretion dynamics are still not well understood.
In patients undergoing infertility treatment using assisted reproductive technologies in our clinic, the E2 level is measured using an enzyme immunoassay analyzer (AIA-1800 or AIA-2000; TOSOH Corporation, Tokyo, Japan). The E2 levels are measured in real time using a competitive enzyme immunoassay based on the fluorescence enzyme immunoassay (FEIA) method. It is performed entirely within a supplied test cup (ST AIA-PACK E2 test kit or ST AIA-PACK iE2 test kit). E2 present in the test sample competes with alkaline phosphatase-labeled E2 in the cup for a limited number of binding sites on E2-specific antibodies immobilized on magnetic beads. The beads are washed to remove any unbound enzyme-labeled E2 and are then incubated with a fluorogenic substrate. The E2 concentration in the sample is calculated based on the time the enzyme takes to produce a fluorescent substance. Serum E2 levels are measured in approximately 20 min. Initially, we used the ST AIA-PACK E2 test kit (hereinafter referred to as “the ST AIA-PACK E2 reagent”), but in August 2012, we changed to the ST AIA-PACK iE2 test kit (hereinafter referred to as the “ST AIA-PACK iE2 reagent). The ST AIA-PACK iE2 reagent uses CRM577, a reference material certified by the Institute for Reference Materials and Measurements, for calibration. Results with the ST AIA-PACK iE2 reagent correlate well with results of isotope dilution-gas chromatography/mass spectrometry. Additionally, the ST AIA-PACK iE2 reagent uses an antibody with a higher E2 specificity than the ST AIA-PACK E2 reagent, which uses a polyclonal antibody generated by immunizing a rabbit with antigen and purifying its blood. For the ST AIA-PACK iE2 reagent, the antibody is obtained by exenterating the spleen of an antigen-immunized rabbit, isolating the B cells, and creating hybridoma cells by fusing the B cells with myeloma cells; these hybridoma cells can divide indefinitely, and the cells that generate an antibody with a higher E2 specificity are then selected. Table 1 shows the cross-reactivity of both reagents. The ST AIA-PACK iE2 reagent is shown to be more specific than the ST AIA-PACK E2 reagent as it has a much lower cross-reactivity with E1 and estriol (E3). In other words, E1 and E3 secretion is more likely to be included in the serum E2 concentration measured with the ST AIA-PACK E2 reagent than in that measured with the ST AIA-PACK iE2 reagent.
We hypothesized that a comparison of the measurements obtained by the two different reagents would allow us to indirectly evaluate the serum levels of hormones other than E2 with which the ST AIA-PACK E2 reagent had high cross-reactivity. We carried out a statistical analysis and compared the E2 measurements obtained with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent according to follicle size in a natural cycle IVF setting. Changes in the E2 levels observed during the course of infertility treatment are reported. We also describe cases in which the different cross-reactivity to E1 and E3 between the two reagents was reflected in the difference in the measured concentrations.
A total of 14371 serum hormone data measurements from 4412 women who underwent oocyte retrieval or frozen/thawed embryo transfer in natural cycle IVF in our clinic between June 2011 and May 2014 were included in this study. These patients were treated with IVF or intracytoplasmic sperm injection (ICSI) because of female-related (12.1 %), male-related (28.0 %), or unexplained (59.8 %) issues. The patients’ age ranged from 24 to 48 year (mean age and standard deviation, 39.8 ± 4.0 year). The average body mass index was 20.7 ± 2.6 (range: 14.8–41.0). Most patients were Japanese (99.2 %), followed by other Asians (0.7 %) and other ethnic groups (0.1 %). Samples were taken from the patients between day 8 and day 20 of their menstrual cycle, before the onset of the luteinizing hormone (LH) surge, i.e., when the LH level was <20 IU/L and the progesterone (P4) level was <1.0 ng/mL. Cases were excluded if either of the following criteria were met: 1) more than two follicles ≥11 mm in diameter were observed on ultrasonography and 2) the diameter of the largest follicle was ≥21 mm. Approval of this study was obtained from the independent Institutional Review Board of Shinbashi YUME Clinic (SYC2014-8, approved 1 July, 2014). All patients received detailed information about the proposed treatment. Written informed consent was obtained from all participants; they also agreed that their de-identified data could be used for research purposes.
Serum concentrations of E2, LH, follicle-stimulating hormone (FSH), and P4 were measured in all patients on the AIA-1800 or AIA-2000 analyzer using the FEIA method. Follicle size during the natural cycle, with no administration of ovulation-inducing drugs, was determined by ultrasound examination using the HI VISION AVIUS system (Hitachi Medical Corporation, Tokyo, Japan). Follicle maturation was considered complete when serum E2 levels were ≥200 pg/mL and the diameter of the largest follicle was ≥18 mm.
When the follicles reached maturation, a gonadotropin-releasing hormone (GnRH) agonist (Suprecur, Mochida Pharmaceutical Co., LTD., Tokyo, Japan) was administered to trigger the endogenous LH surge, and oocytes were retrieved 34–36 h later. The retrieved oocytes were inseminated by conventional methods or ICSI. They were cultured until they reached the expanded blastocyst stage, and then transferred as a fresh embryo or vitrified for a later frozen/thawed transfer. For the frozen/thawed transfer carried out in the natural cycle, serum hormone measurement and the ultrasound examination were performed as in the oocyte retrieval cycle; the embryo was thawed 4–5 days after ovulation, and the blastocyst was transferred. Oocyte retrieval, embryo transfer, and embryo culture were all carried out following the methods stipulated by Teramoto et al.  and Kato et al. [8, 9].
Serum E2 concentrations for the 14371 samples obtained during the oocyte retrieval cycles and frozen/thawed embryo transfer cycles, measured with the ST AIA-PACK E2 reagent or ST AIA-PACK iE2 reagent, were categorized by the largest follicle diameter (10 groups, from 11 to 20 mm, with 1-mm intervals) and by age (<38 year, 38–40 year, and >40 year). Since most of the patients in our clinic have histories of failed IVF treatment in other institutions, our patient population tends to be much older than that of other institutions. For this reason, patients in the <38 year, 38–40 year, and >40 year categories were considered young, older, and old, respectively. In total, 4032 measurements were in the <38 year group (1256 and 2776 with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent, respectively), 3740 were in the 38–40 year group (1307 and 2433 with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent, respectively), and 6599 were in the >40 year group (2720 and 3879 with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent, respectively). The serum E2 levels measured with each reagent were then compared within each follicle size category. Similarly, the serum E2 concentration and serum FSH concentration were compared between the three age groups in each follicle size category. Furthermore, serum E2 (measured with both reagents), serum E1, and serum E3 concentrations (measured by the radioimmunoassay method; BML Inc., Tokyo, Japan) were measured in 12 randomly selected cases in the early follicular phase and in 14 randomly selected cases in the ovulatory phase, and the measurements in the two phases were compared. All data were analyzed using the t-test by JMP 11.2 (SAS Institute, Cary, NC, USA). P < 0.01 was considered to indicate statistical significance.
Table 2 shows the comparison between the serum E2 concentrations measured with the two reagents. The data are categorized by age and largest follicle diameter. In the <38 year group, E2 concentrations measured with the ST AIA-PACK iE2 reagent were significantly lower than those measured with the ST AIA-PACK E2 reagent in the largest follicle diameter categories ranging from 11 to 17 mm. However, in the largest follicle diameter categories from 18 to 20 mm, the E2 concentrations measured using the two reagents did not differ. In the 38–40 year group, the E2 concentrations measured with the ST AIA-PACK iE2 reagent were significantly lower than those measured with the ST AIA-PACK E2 reagent in the largest follicle diameter categories ranging from 11 to 18 mm, but no significant difference was noted for the categories from 19 to 20 mm. In the >40 year group, the E2 concentrations measured with the ST AIA-PACK iE2 reagent were significantly lower than those measured with the ST AIA-PACK E2 reagent in the largest follicle diameter categories ranging from 11 to 15 mm, but no significant difference was noted for the categories from 16 to 20 mm. Table 3 shows the comparison of serum E2 concentrations (measured with the ST AIA-PACK iE2 reagent) and serum FSH concentrations between the age groups for each largest follicle diameter category. There were four patterns of significant differences between the three age groups. When focusing on the <38 year and the >40 year groups, serum E2 concentrations were significantly higher in the older age group than in the younger age group for the 11 mm to 18 mm largest follicle diameter categories, but there was no significant difference between the groups for the 19 mm and 20 mm categories. Serum FSH concentrations were significantly higher in the older age group for all largest follicle diameter categories. Table 4 shows the comparison of the mean serum estrogen concentrations (E1, E2, and E3) in 12 randomly selected cases from the early follicular phase and 14 randomly selected cases from the ovulatory phase. The ratios of serum E2 concentrations measured with the ST AIA-PACK iE2 reagent to those measured with the ST AIA-PACK E2 reagent were 2.9 ± 0.6 and 0.9 ± 0.1 for the early follicular phase group and the ovulatory phase group, respectively (P < 0.01). Furthermore, the serum E1 concentration to serum E2 concentration ratios measured with the ST AIA-PACK iE2 reagent (E1/E2) were 3.4 ± 1.1 and 0.7 ± 0.1 in the early follicular phase group and the ovulatory phase group, respectively (P < 0.01). Serum E3 concentrations were below the detection range in both groups.
In the present study, we analyzed the differences in estrogen concentration measurements according to the reagent used, considering the different properties of the two reagents used for measuring serum E2 concentrations. The improved specificity of the new E2 measuring reagent from TOSOH Corp. is attributable to the use of a monoclonal antibody rather than a polyclonal antibody. Therefore, we presumed that the content of estrogen besides E2 (mainly E1) could be measured indirectly by analyzing the differences in measurements obtained using the ST AIA-PACK E2 reagent and the ST AIA-PACK iE2 reagent. We could not measure E2 in all the 14371 samples using both the ST AIA-PACK E2 reagent and the AIA-PACK iE2 reagent, although this would have been ideal, because this would have been very expensive. Instead, we measured E2 (using both reagents), E1, and E3 at the same time in a few samples, analyzed the differences, and compared the E1 to E2 ratios. The E1/E2 ratio was high in the samples taken from the early follicular phase and there was a significant difference between the concentrations measured with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent, suggesting that the concentration of E1 was high in these samples. In samples taken during the ovulatory phase, the E1/E2 ratio was small and there was only a small difference in the concentrations measured with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent, indicating a lower concentration of E1 in these samples.
The LH surge is triggered by positive feedback from the hypothalamic-pituitary axis, by the increase in estrogen levels in the late follicular phase . If a decrease in serum E1 causes the E2/E1 ratio to increase in the ovulatory phase (follicle diameter, 19–20 mm), as seen in the current study, this phenomenon may trigger the onset of the LH surge. Conversely, the onset of the LH surge may be suppressed when E1 secretion is high (follicle diameter, ≤18 mm). The possible role of E1 secretion in the mid-to-late follicular phase in maintaining follicle development by suppressing the LH surge until the follicle is fully matured is extremely interesting. In the >40 year group however, the difference in the serum E2 measurements observed between the two reagents disappeared after the mid-follicular phase (follicle diameter, 16 mm) and a relative increase in E2 (or decrease in E1) was observed. In older infertility patients, premature elevation of serum LH levels is often observed, before the follicle is fully developed and the premature LH surge arrests follicular growth. In these situations, good mature oocytes cannot be obtained. Aging is known to affect pulsatile GnRH secretion and the pituitary reaction . In the present study, E1 decrease occurred earlier in the >40 year group than in the younger age groups. In the ≤16 mm follicle diameter category, the serum E2 levels were significantly higher in the >40 year group than in the younger age groups (Table 3). Several reports describe an increase in the serum E2 concentration in the follicular phase of older women [12–15]. A decrease in serum inhibin B in older women causes an increase in FSH secretion through negative feedback, which in turn stimulates the granulosa cells in the ovary, resulting in an elevated serum E2 level [12, 14, 15]. Welt et al. also showed that the androstenedione/E1 ratio decreased in older women in the early-to-mid follicular phase . Androstenedione is converted to E1 by the enzymatic activity of aromatase , which also converts testosterone into E2. Therefore, aromatase activity in the ovary may increase in older women. In this study, there was no difference in the E2 levels measured with the ST AIA-PACK E2 reagent and ST AIA-PACK iE2 reagent in the follicle diameter categories from 16 to 20 mm in the >40 year group, suggesting that E1 levels had decreased (Table 2).
There are many reports on the association of E1 with estrogen-dependent breast cancer tumor growth and coronary artery disease [18–20]. The bioactivity of E1 is considered weaker than that of E2 . Kushnir et al. examined the E1 and E2 concentrations in follicular fluid (FF) in the early follicular phase and at oocyte retrieval and found a more than 10-fold higher E1/E2 ratio in the early follicular phase than at oocyte retrieval. They also showed that androstenedione concentrations in the early follicular phase were approximately 60 times greater than those measured at oocyte retrieval . Costa et al. measured hormone concentrations in the FF at oocyte retrieval, and compared FF in the follicles containing a mature and an immature oocyte. The E2 and testosterone levels were significantly lower in the FF containing mature oocytes than in the FF containing immature oocytes, but there was no significant difference in E1 and progesterone levels between the two kinds of FF . McNatty et al. examined hormone concentrations in the FF of follicles ≥8 mm in diameter and found that E1/E2 ratio was similar in the early, mid, and late follicular phases, but the androstenedione/E1 ratio decreased as the follicular phase progressed from the early, mid, to late phase. They also found that the E1/E2 ratio was lower in blood samples taken from the veins in the ovary containing a follicle ≥8 mm than in samples taken from the veins in the ovary not containing a follicle ≥8 mm . While there are several reports on the E1 concentration in the FF, the role of E1 in follicle development has not been reported. Although the present study is an indirect data analysis, the shift in the secretion level of estrogen (E2 and E1) is of great significance. The E1/E2 ratio, in addition to the change in follicle size, might play an important role in follicle development and maturation and ovulation of the oocyte.
The present study revealed a shift in estrogen secretion during follicle development. In general, fertility centers use ovulation-inducing drugs to have multiple follicles develop, thus making it impossible to measure the hormonal concentrations per single dominant follicle. We, on the other hand, treat patients with the natural cycle protocol, which does not require the use of ovulation-inducing drugs. The timing of ovulation was determined by measuring the diameter of the developing dominant follicle by ultrasonography and the serum E2 concentrations each time the patient visited the clinic. Therefore, we could accumulate a large amount of data, and we believe this kind of data is very valuable. We also found that the difference between the E2 concentrations measured with the ST AIA-PACK E2 reagent and the ST AIA-PACK iE2 reagent tended to decrease as the follicle diameter increased, particularly in the older patients, which suggests that E1 is more abundant in the early follicular phase and in younger patients than in the ovulatory phase and in older patients. We are planning to extend the scope of the study and examine various aspects such as the relationship between the level of estrogen and oocyte quality, and their influence on pregnancy.
Fluorescence enzyme immunoassay
Intracytoplasmic sperm injection
In vitro fertilization
Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab. 1994;78:428–32.
Frisch RE. Body fat, menarche, fitness and fertility. Hum Reprod. 1987;2:521–33.
Kirschner MA, Ertel N, Schneider G. Obesity, hormones, and cancer. Cancer Res. 1981;41:3711–7.
Longcope C, Pratt JH, Schneider SH, Fineberg SE. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab. 1978;46:146–52.
Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2011;76:177–82.
Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Davis S, et al. Local estrogen biosynthesis in males and females. Endocr Relat Cancer. 1999;6:131–7.
Teramoto S, Kato O. Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. Reprod Biomed Online. 2007;15:134–48.
Kato K, Takehara Y, Segawa T, Kawachiya S, Okuno T, Kobayashi T, et al. Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-centre, Japanese cohort. Reprod Biol Endocrinol. 2012;10:35.
Kato O, Kawasaki N, Bodri D, Kuroda T, Kawachiya S, Kato K, et al. Neonatal outcome and birth defects in 6623 singletons born following minimal ovarian stimulation and vitrified versus fresh single embryo transfer. Eur J Obstet Gynecol Reprod Biol. 2011;161:46–50.
March CM, Goebelsmann U, Nakamura RM, Mishell Jr DR. Roles of estradiol and progesterone in eliciting the midcycle luteinizing hormone and follicle-stimulating hormone surges. J Clin Endocrinol Metab. 1979;49:507–13.
Tsutsumi R, Webster NJ. GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr J. 2009;56:729–37.
Klein NA, Battaglia DE, Miller PB, Branigan EF, Giudice LC, Soules MR. Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age. J Clin Endocrinol Metab. 1996;81:1946–51.
Lee SJ, Lenton EA, Sexton L, Cooke ID. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Hum Reprod. 1988;3:851–5.
Reame NE, Wyman TL, Phillips DJ, de Kretser DM, Padmanabhan V. Net increase in stimulatory input resulting from a decrease in inhibin B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating hormone of aging cycling women. J Clin Endocrinol Metab. 1998;83:3302–7.
Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab. 1999;84:105–11.
Welt CK, Jimenez Y, Sluss PM, Smith PC, Hall JE. Control of estradiol secretion in reproductive ageing. Hum Reprod. 2006;21:2189–93.
Brailly S, Gougeon A, Milgrom E, Bomsel-Helmreich O, Papiernik E. Androgens and progestins in the human ovarian follicle: differences in the evolution of preovulatory, healthy nonovulatory, and atretic follicles. J Clin Endocrinol Metab. 1981;53:128–34.
Ayan D, Maltais R, Roy J, Poirier D. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone. Mol Cancer Ther. 2012;11:2096–104.
De Padua Mansur A, Silva TC, Takada JY, Avakian SD, Strunz CM, Machado César LA, et al. Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. Sci World J. 2012;2012:363595.
Lunardi G, Piccioli P, Bruzzi P, Notaro R, Lastraioli S, Serra M, et al. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Res Treat. 2013;137:167–74.
Shimizu Y. Estrogen: estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4). Nihon Rinsho. 2010;68 Suppl 7:448–61.
Kushnir MM, Naessen T, Kirilovas D, Chaika A, Nosenko J, Mogilevkina I, et al. Steroid profiles in ovarian follicular fluid from regularly menstruating women and women after ovarian stimulation. Clin Chem. 2009;55:519–26.
Costa LO, Mendes MC, Ferriani RA, Moura MD, Reis RM, de Sá MF S. Estradiol and testosterone concentrations in follicular fluid as criteria to discriminate between mature and immature oocytes. Braz J Med Biol Res. 2004;37:1747–55.
McNatty KP, Baird DT, Bolton A, Chambers P, Corker CS, McLean H. Concentration of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. J Endocrinol. 1976;71:77–85.
The authors wish to thank Ms. Kyoko Nakazato and Dr. Adrian J. Pinnington, as well as Editage (www.editage.jp) for their assistance with English language editing.
The authors declare that they have no competing interests.
TS performed the research, collected the data, performed the analysis, and wrote the manuscript. ST performed the research, collected the data, performed the analysis, and revised the manuscript. KO, OM, and YW participated in the design of the study and helped draft the manuscript. HO conceived the study, participated in its design and coordination, helped draft the manuscript, and developed the final approved version to be published. All authors read and approved the final version of the manuscript.
TS graduated from Kanazawa University School of Medicine in Japan in 1992 with an M.D. degree. He then worked for Kanazawa University and was awarded his Ph.D. in 2003. From 2004 to 2009 he worked for Kato Ladies Clinic in Tokyo as a certified specialist in reproductive medicine and then moved to Shinbashi YUME Clinic, where he is currently serving as Vice-Director. He has also been certified as a specialist physician by the Japan Society of Human Genetics.